Cargando…

The COVID-19 pandemic and the use of MS disease-modifying therapies

Detalles Bibliográficos
Autores principales:	Giovannoni, Gavin, Hawkes, Chris, Lechner-Scott, Jeannette, Levy, Michael, Waubant, Emmanuelle, Gold, Julian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138156/ https://www.ncbi.nlm.nih.gov/pubmed/32334820 http://dx.doi.org/10.1016/j.msard.2020.102073

Ejemplares similares

Is multiple sclerosis a risk factor for infections?
por: Lechner-Scott, Jeannette, et al.
Publicado: (2020)

Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis
por: Salama, Sara, et al.
Publicado: (2020)

COVID-19 vaccines and multiple sclerosis disease-modifying therapies
por: Giovannoni, Gavin, et al.
Publicado: (2021)

B cell therapy and the use of RNA-based COVID-19 vaccines
por: Vishnevetsky, Anastasia, et al.
Publicado: (2021)

How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?
por: Giovannoni, Gavin
Publicado: (2022)

Vaccine hesitancy in people with multiple sclerosis
por: Lechner-Scott, Jeannette S, et al.
Publicado: (2022)

Long COVID or post COVID-19 syndrome
por: Lechner-Scott, J., et al.
Publicado: (2021)

Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19
por: Giovannoni, Gavin
Publicado: (2020)

The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic
por: Baker, David, et al.
Publicado: (2020)

COVID-19 and MS disease-modifying therapies
por: Berger, Joseph R., et al.
Publicado: (2020)

Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG
por: Waubant, Emmanuelle, et al.
Publicado: (2019)

Environmental and genetic risk factors for MS: an integrated review
por: Waubant, Emmanuelle, et al.
Publicado: (2019)

Cognition and its relation to brain health in patients with MS: Response to letter
por: Hobart, Jeremy, et al.
Publicado: (2020)

A comparison between the pathophysiology of multiple sclerosis and normal pressure hydrocephalus: is pulse wave encephalopathy a component of MS?
por: Bateman, Grant A., et al.
Publicado: (2016)

Epstein-Barr–negative MS: a true phenomenon?
por: Dobson, Ruth, et al.
Publicado: (2017)

Biomarkers Indicative of Blood-Brain Barrier Disruption in Multiple Sclerosis
por: Waubant, Emmanuelle
Publicado: (2006)

HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study
por: Gold, Julian, et al.
Publicado: (2015)

Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool
por: Hobart, Jeremy, et al.
Publicado: (2022)

A pilot study of oxidative pathways in MS fatigue: randomized trial of N‐acetyl cysteine
por: Krysko, Kristen M., et al.
Publicado: (2021)

Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies
por: Smith, Tyler E, et al.
Publicado: (2022)

COVID-19: Retransmission of official communications in an emerging pandemic
por: Sutton, Jeannette, et al.
Publicado: (2020)

Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies
por: McFaul, Derek, et al.
Publicado: (2021)

Wastewater-based monitoring of illicit drugs in Cyprus by UPLC-MS/MS: The impact of the COVID-19 pandemic
por: Psichoudaki, M., et al.
Publicado: (2023)

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy
por: Havrdova, Eva, et al.
Publicado: (2017)

Assessing fracture risk in people with MS: a service development study comparing three fracture risk scoring systems
por: Dobson, Ruth, et al.
Publicado: (2013)

Outcome of MS relapses in the era of disease-modifying therapy
por: Stoppe, Muriel, et al.
Publicado: (2017)

Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes
por: Holroyd, Kathryn B., et al.
Publicado: (2022)

Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia
por: Seery, Nabil, et al.
Publicado: (2020)

Disease-modifying therapies alter gut microbial composition in MS
por: Katz Sand, Ilana, et al.
Publicado: (2018)

Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease
por: Sacco, Simone, et al.
Publicado: (2023)

Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method
por: Gold, Ralf, et al.
Publicado: (2023)

The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform
por: Jokubaitis, Vilija G., et al.
Publicado: (2013)

Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2023)

Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS
por: Chan, Andrew, et al.
Publicado: (2020)

Effect of vitamin D on MS activity by disease-modifying therapy class
por: Rotstein, Dalia L., et al.
Publicado: (2015)

Effects of MS disease-modifying therapies on responses to vaccinations: A review.
por: Ciotti, John Robert, et al.
Publicado: (2020)

Preventing Multiple Sclerosis: The Pediatric Perspective
por: Hardy, Duriel, et al.
Publicado: (2022)

Final Report: Milestone: MS53
por: Bruce, R, et al.
Publicado: (2015)

MS Care in Novel Coronavirus 19 Pandemic
por: Ramezani, Neda, et al.
Publicado: (2020)

Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement
por: Reyes, Saúl, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8j6kmiscb7mv6i6r059drk9tbd